Skip to main content

Ilaria Pagani

Ilaria Pagani
Adelaide Medical School
Faculty of Health and Medical Sciences

Dr. Ilaria S Pagani joined the Leukaemia Research Group at SAHMRI in July 2014, developing two projects on chronic myeloid leukaemia (CML).
CML is a myeloproliferative disease characterize by the t(9;22)(q34;q11) balanced reciprocal translocation. The hallmark of the CML is the BCR/ABL1 fusion gene on Philadelphia chromosome (Ph), which encodes for a constitutively active protein tyrosine kinase (TK) that confers proliferative advantages to the Ph-positive clone. Tyrosine kinase inhibitors (TKIs) dramatically improved the survival of chronic myeloid leukaemia (CML) patients. TK inhibitors (TKIs) have revolutionized the management of the CML, providing target therapy for patients. Despite the success of TKIs in long-term survival, variations in treatment outcome suggest a possible secondary mechanism of resistance due to the persistence of a pre-existing clone that had acquired additional genetic lesions.
The first project is the characterization of the genomic landscape of mitochondrial (mt) DNA mutations in CML by next generation sequencing techniques, identifying a sub-group of patients that do not respond to the therapy. Next goal will be to determine whether mtDNA mutations influence the susceptibility of CML cells to undergo apoptosis in response to tyrosine kinase inhibition.
Approximatively half of patients who achieved a deep molecular response and maintain it for 1-2 years, experienced molecular relapse after stopping TKI-therapy. Dr. Pagani is investigating whether the lineage and proliferative potential of residual leukaemic cells are key determinant of treatment free remission after stopping therapy.

Connect With Me

Ilaria Pagani

Dr. Ilaria S Pagani joined the Leukaemia Research Group at SAHMRI in July 2014, developing two projects on chronic myeloid leukaemia (CML).
CML is a myeloproliferative disease characterize by the t(9;22)(q34;q11) balanced reciprocal translocation. The hallmark of the CML is the BCR/ABL1 fusion gene on Philadelphia chromosome (Ph), which encodes for a constitutively active protein tyrosine kinase (TK) that confers proliferative advantages to the Ph-positive clone. Tyrosine kinase inhibitors (TKIs) dramatically improved the survival of chronic myeloid leukaemia (CML) patients. TK inhibitors (TKIs) have revolutionized the management of the CML, providing target therapy for patients. Despite the success of TKIs in long-term survival, variations in treatment outcome suggest a possible secondary mechanism of resistance due to the persistence of a pre-existing clone that had acquired additional genetic lesions.
The first project is the characterization of the genomic landscape of mitochondrial (mt) DNA mutations in CML by next generation sequencing techniques, identifying a sub-group of patients that do not respond to the therapy. Next goal will be to determine whether mtDNA mutations influence the susceptibility of CML cells to undergo apoptosis in response to tyrosine kinase inhibition.
Approximatively half of patients who achieved a deep molecular response and maintain it for 1-2 years, experienced molecular relapse after stopping TKI-therapy. Dr. Pagani is investigating whether the lineage and proliferative potential of residual leukaemic cells are key determinant of treatment free remission after stopping therapy.

Eligible to supervise Masters and PhD — email supervisor to discuss availability.

Appointments

Date Position Institution name
2017 - 2020 Affiliated Lecturer University of Adelaide, Adelaide
2015 - 2018 Post-Doctoral Researcher South Australian Health and Medical Research Institute, Adelaide
2014 - 2014 Visiting-Post Doc South Australian Health and Medical Research Institute, Adelaide
2012 - 2014 Post-Doctoral Researcher University of Rome Tor Vergata, Rome
2012 - 2012 Visiting Post-Doc Medical Research Council (MRC), London
2011 - 2012 Post-Doctoral Researcher University of Insubria, Varese

Awards and Achievements

Date Type Title Institution Name Country Amount
2018 Award Best poster Award New Directions in Leukaemia Research (NDLR) 2018 Meeting Australia $250
2018 Invitation Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia
2018 Invitation Technical expert/guide to the Italian Delegation in SAHMRI South Australian Health and Medical Research Institute (SAHMRI) Australia
2016 Invitation Invited to judge oral/poster presentations for the EMBL Australia Postgraduate Symposium 2016 at SAHMRI, Adelaide, Australia. EMBL Australia Australia
2016 Achievement Invited speaker to the 2016 Leukaemia Foundation Patient Education Conference, CML Session, Adelaide University, Australia. Leukaemia Foundation Australia
2016 Achievement Invited speaker to the Hematology Seminar, S.A. Pathology, Adelaide, SA, Australia SA Pathology Australia
2016 Achievement Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia
2016 Award Competitive selective Beat Cancer Project Travel Grant 2016 Cancer Council South Australia Australia $1250
2015 Achievement Invited speaker to the Blood Club Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. South Australian Health and Medical Research Institute (SAHMRI) Australia
2014 Award Top 10 Best Abstracts European Society Human Genetics (ESHG), Milan, Italy Italy
2013 Award American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award American Society of Hematology (ASH) Italy $500
2012 Fellowship competitive selective 3 years - Italian Association for Cancer Research" (AIRC) Fellowship Italian Association for Cancer Research (AIRC) Italy
2011 Award Competitive Selective Travel Fellowship covering all expenses to participate at the 11th FEBS Young Scientist Forum and at 36th FEBS Congress. FEBS Italy
2011 Fellowship Italian Association against Leukaemia and Lymphoma (AIL) Fellowship Italian Association against Leukaemia and Lymphoma (AIL) Italy
2007 Scholarship Insubria University PhD Scholarship, Varese, Italy. Insubria University Italy

Language Competencies

Language Competency
English Can read, write, speak, understand spoken and peer review
French Can read, write, speak and understand spoken
Italian Can read, write, speak, understand spoken and peer review

Education

Date Institution name Country Title
2011 - 2016 University of Milan, Milan Italy Specialist in Medical Genetics
2011 University of Insubria, Varese Italy PhD
2007 University of Insubria, Varese Italy Master Degree in Molecular Biology

Certifications

Date Title Institution name Country
2008 State Examination for the qualification in Biologi University of Insubria, Varese Italy

Research Interests

Journals

Year Citation
2017 Pagani, I., Kok, C., Saunders, V., Van der Hoek, M., Heatley, S., Schwarer, A., . . . Ross, D. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721.
DOI Scopus1
2015 Porta, G., Pagani, I. S., & Pirrone, C. (2015). gDNA Q-PCR for clinical monitoring of CML. Cell Cycle, 14(23), 3659-3660.
DOI
2014 Pagani, I. S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., . . . Porta, G. (2014). Genomic quantitative real-time PCR proves residual disease posivitity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience.
2013 Azzolini, C., Pagani, I. S., Pirrone, C., Borroni, D., Donati, S., Al Oum, M., . . . Porta, G. (2013). Expression of VEGF-A, Otx Homeobox and p53 Family Genes in Proliferative Vitreoretinoipathy.. Mediators of Inflammation.
2011 Terrinoni, A., Pagani, I., Zucchi, I., Chiaravalli, A., Serra, V., Rovera, F., . . . Porta, G. (2011). OTX1 expression in breast cancer is regulated by p53. Oncogene, 30(27), 3104.
DOI
2010 Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2010). The Mammary Gland and the Homeobox Gene Otx1. The Breast Journal, 16, S53-S56.
DOI

Conference Papers

Year Citation
2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood. Atlanta: American Society of Hematology.
2017 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation.
2016 Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group.
2016 Pagani, I., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
2014 Pagani, I. S., Pirrone, C., & Amelotti, E. (2014). TAp73α regulates Otx1 expression during breast cancer stem cells differentiation and in response to cisplatin treatment.. In European Journal of Human Genetics. Milan: Nature Publishing Group.
2014 Pirrone, C., & Pagani, I. S. (2014). New molecular technique to monitor minimal residual diseased in CML. In European Journal of Human Genetics. Milan: Nature Publishing Group.
2014 Pagani, I. S. (2014). Genomic quantitative real-time PCR assay proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR results in Chronic Myeloid Leukemia.. In Bone Marrow Transplantation. Milan: Nature Publishing Group.
2013 Pagani, I. S. (2013). Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. In Blood. New Orleans: American Society of Hematology.
2013 Azzolini, C., & Pagani, I. S. (2013). Expression Of VEGF-A Gene In Normal Retina And In PVR Retina. In Investigative Ophthalmology & Visual Science. Seattle: Association for Research in Vision and Ophthalmology.
2012 Azzolini, C., & Pagani, I. S. (2012). Otx2 And VegfA Expression And P53-Otx1 Differentiation Pathway In Proliferative Vitreoretinopathy. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology.
2011 Pagani, I. S. (2011). Chronic myeloid leukemia: molecular monitoring of residual disease by genomic DNA compared to conventional mRNA analysis in follow-ups up to 8 year. In Blood. Sand Diego, US: American Society of Hematology.
2011 Pagani, I. S. (2011). p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem cells and in mammary gland development. In FEBS Journal. Torino, Italy: Blackwell Publishing Inc..
2011 Azzolini, C., Donati, C., Borroni, D., Moriondo, A., & Pagani, I. S. (2011). Evaluation of the p53-Otx1 pathway in the retina.. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology.
  • 2016: Biochemistry III tutorial, Adelaide University, Australia.
  • 2007-2013: Tutorial of Laboratory Techniques and genetics to Medicine Students, Insubria University, Varese, Italy.

 

Other Supervision Activities

Date Role Research Topic Location Program Supervision Type Student Load Student Name
2018 - ongoing Principal Supervisor Mitochondrial DNA mutations in CML The University of Adelaide Placement Other Part Time Samuel Cannata, Rico Acuna
2018 - ongoing Co-Supervisor Mitochondrial DNA copy Numbers in MPN UniSA Placement Other Part Time Lian Thuy
2017 - ongoing Principal Supervisor Monitoring BCR-ABL content in 2 Chronic Myeloid Leukaemia (CML) Patients Involved in a Trial of Treatment Free Remission (TFR) The University of Adelaide Placement Other Part Time Caitlin Skinner
2014 - ongoing Co-Supervisor Next generation Sequencing in CML Insubria University Postdoctorate Pirrone Cristina
2011 - ongoing Principal Supervisor Monitoring of minimal residual disease in CML by gDNA QPCR Insubria University, Varese, Italy Master Full Time Giorgia Aimoni
2011 - ongoing Principal Supervisor Monitoring of Minimal Residual Disease in CMl Insubria University Master Pirrone Cristina
2011 - 2013 Principal Supervisor Next-Generation Sequencing as a new approach to monitor minimal residual disease in CML Insubria University Doctorate Full Time Pirrone Cristina
2011 - ongoing Co-Supervisor p53-Otx1 in retina Faculty of Medicine, Insubria University, Master Borroni Davide
2009 - 2011 Principal Supervisor p53 and Otx1 in Glioblastoma and Breast Cancer Faculty of Medicine, Insubria University Placement Other Annalisa Paolino, Eleonora Scotti, Martina Baiardo
Building

top